ASH 2021 | An update on MRD assessment and novel techniques used in the treatment of hematological malignancies
In this video, Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, shares his insights into the use of various techniques in hematological malignancies and the future of research in this area. First, Dr Roschewski discusses the use of minimal residual disease (MRD) testing in many disease areas, including chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myeloid leukemia (AML), and compares this to the use of MRD testing in lymphoma. Dr Roschewski then summarizes some data that he presented, drawing focus to advances in technology such as ctDNA assays, and ties this together to the use of immunotherapies, including CAR T-cell therapy, and how these advances may provide better outcomes for patients in the future. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
